Inhibikase Therapeutics, Inc.

IKT

Inhibikase Therapeutics, Inc.

IKT

Insider Sentiment (TTM):

Last Purchase:2025-11-21Last Sale:-Shares Purchased (TTM):2,068,965Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:113,441,803Shares Outstanding:172,306,932Institutional Ownership Pct.:65.84%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash	31	50	139	38	78	73	56	1	3	2	9	15
Marketable Securities Current	128	121	40	39	10	20	41	2	5	7	4	2
Accounts And Other Receivables Net Current	-	-	-	-	-	-	-	-	-	0	0	0
Prepaid Expense Current	2	1	1	0	0	0	0	0	0	0	0	0
Deferred Offering Costs	-	-	-	0	0	-	-	1	-	-	-	-
Prepaid Expense And Other Assets Current	1	1	0	1	1	1	1	0	0	1	1	0
Assets Current	162	172	180	79	89	94	98	4	9	11	14	18
Property Plant And Equipment Net	-	-	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	-	-	0	0	0	0	0	0	0	0	0	0
Prepaid Expense Noncurrent	1	1	1	1	-	-	0	-	-	-	-	-
Other Assets Noncurrent	0	0	0	0	-	-	0	-	-	-	-	-
Assets	164	173	181	80	89	94	99	4	9	11	15	18
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	2	1	1	3	2	1	3	1	1	1	1
Long Term Debt And Capital Lease Obligations Curre…	-	-	0	0	0	0	0	0	0	0	0	0
Accrued Liabilities Current	9	4	4	4	3	4	3	2	2	3	2	2
Liabilities Current	10	6	8	7	9	9	4	5	4	4	3	3
Capital Lease Obligations Noncurrent	-	-	-	-	-	-	-	-	-	0	0	0
Liabilities	10	6	8	7	9	9	4	5	4	4	4	3
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	332	327	315	203	198	194	189	82	82	78	78	78
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	-0	-0	-0	-0	0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-179	-159	-143	-130	-118	-108	-94	-82	-77	-72	-67	-63
Stockholders Equity	153	168	173	73	80	86	95	-1	5	7	11	15
Liabilities And Stockholders Equity	164	173	181	80	89	94	99	4	9	11	15	18
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	500	500	500	500	500	500	100	100	100	100	100	100
Common Stock Shares Issued	132	132	132	75	75	74	69	7	7	6	6	5
Shares Outstanding	132	132	132	75	75	74	69	7	7	6	6	5

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-15.10%	3.65%	18.75%	-	-	-	-	-	-	-	-	-
2025	-7.55%	-10.85%	-28.30%	-2.34%	-2.92%	-14.04%	-1.96%	27.45%	-1.96%	12.27%	6.13%	2.45%
2024	-15.08%	-41.71%	-33.17%	3.08%	-3.08%	103.08%	38.98%	40.68%	-3.81%	-19.83%	-15.19%	-21.52%
2023	-	-	-	-18.88%	-64.54%	-58.63%	26.53%	36.73%	160.20%	-11.30%	-24.78%	-38.70%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	15.82	30.14	21.70	11.73	10.09	11.01	26.37	0.85	2.32	2.55	4.13	6.40
Quick Ratio	15.59	30.05	21.58	11.70	10.08	11.01	26.35	0.83	2.24	2.50	4.07	6.27
Working Capital	152.08M	166.46M	171.81M	71.84M	80.00M	85.61M	94.72M	-717.36K	4.90M	6.57M	10.77M	14.81M
Leverage & Debt
Debt to Equity	0.07	0.03	0.05	0.09	0.11	0.10	0.04	-9.25	0.73	0.63	0.32	0.19
Interest Coverage TTM	-13.63	-12.97	-13.99	-14.73	-16.48	-20.70	-26.74	-40.23	-30.51	-21.07	-18.94	-22.47
Debt Ratio	0.06	0.03	0.05	0.08	0.10	0.09	0.04	1.12	0.42	0.39	0.24	0.16
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01
Per Share Metrics
Diluted EPS TTM	-0.35	-0.30	-0.49	-0.53	-0.46	-0.41	-1.16	-2.20	-2.44	-3.03	-3.16	-3.10
Free Cash Flow Per Share TTM	-0.20	-0.21	-0.28	-0.24	-0.18	-0.22	-0.81	-1.94	-2.19	-2.52	-3.00	-2.96
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-2,006,393,700.00%	-23,885.05%	-10,285.34%	-7,711.98%	-6,178.12%
Net Profit Margin TTM	-	-	-	-	-	-	-	-1,956,524,900.00%	-23,102.15%	-9,797.30%	-7,304.73%	-5,903.12%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-100.00%	-68.40%	38.08%	111.03%	424.23%
Net Income Growth (1Y)	46.10%	39.43%	75.36%	143.58%	125.79%	90.35%	44.62%	2.28%	-3.40%	7.32%	5.40%	1.66%
EPS Growth (1Y)	-24.67%	-27.55%	-57.70%	-75.97%	-81.10%	-86.52%	-63.23%	-29.04%	-21.01%	-22.40%	-26.16%	-30.31%
Valuation Metrics
P/E TTM	-5.84	-5.68	-4.18	-3.06	-4.23	-5.37	-2.80	-0.59	-0.50	-0.71	-0.40	-0.45
P/B TTM	2.31	1.73	1.17	2.00	2.19	2.29	0.81	-21.76	1.79	2.02	0.70	0.57
P/S TTM	-	-	-	-	-	-	-	11,547,340.58	114.59	69.88	29.39	26.43
Market Cap	354.38M	289.48M	201.54M	145.88M	175.52M	196.09M	77.06M	11.55M	9.12M	13.70M	7.66M	8.57M
Enterprise Value	323.17M	239.90M	62.32M	107.61M	97.81M	122.72M	27.04M	10.78M	6.18M	11.55M	-1.27M	-6.03M
Calculated Values
Free Cash Flow TTM	-34.67M	-35.77M	-27.83M	-21.54M	-15.83M	-19.40M	-19.15M	-17.24M	-16.47M	-15.99M	-18.10M	-18.21M
Net Debt	-31.21M	-49.57M	-139.22M	-38.27M	-77.70M	-73.37M	-50.03M	-768.21K	-2.93M	-2.14M	-8.92M	-14.59M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-11-21Purchase

Owner: Sands, Frank M., Sands Ca…

Title: -

Shares: 2,068,965

Price/Share: $1.45

Value: $2,999,999.25

Shares Owned: 13,018,965

Relationship: TenPercentOwner

Ownership: Direct

2024-10-21Purchase

Owner: Bellini, Roberto

Title: -

Shares: 1,460,000

Price/Share: $1.37

Value: $2,000,200.00

Shares Owned: 1,460,000

Relationship: Director

Ownership: Indirect

2024-10-21Purchase

Owner: Munshi, Amit

Title: -

Shares: 365,000

Price/Share: $1.37

Value: $500,050.00

Shares Owned: 365,000

Relationship: Director

Ownership: Indirect

2024-10-21Purchase

Owner: Kush, Arvind

Title: -

Shares: 145,000

Price/Share: $1.37

Value: $198,650.00

Shares Owned: 145,000

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-11-21	Sands, Frank M., Sands Ca…	TenPercentOwner	-	Direct	Purchase	2,068,965	1.45	$2,999,999.25	13,018,965	4
2024-10-21	Bellini, Roberto	Director	-	Indirect	Purchase	1,460,000	1.37	$2,000,200.00	1,460,000	4
2024-10-21	Munshi, Amit	Director	-	Indirect	Purchase	365,000	1.37	$500,050.00	365,000	4
2024-10-21	Kush, Arvind	Director	-	Direct	Purchase	145,000	1.37	$198,650.00	145,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

65.84%

Inst. Shares: 113,441,803

Shares Outstanding: 172,306,932

2025-12-31

108.18%

Inst. Shares: 106,349,360

Shares Outstanding: 98,310,190

2025-09-30

60.99%

Inst. Shares: 54,918,701

Shares Outstanding: 90,050,973

2025-06-30

60.34%

Inst. Shares: 54,308,961

Shares Outstanding: 90,009,625

2025-03-31

57.27%

Inst. Shares: 51,280,494

Shares Outstanding: 89,537,171

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	113,441,803	172,306,932	65.84%
2025-12-31	106,349,360	98,310,190	108.18%
2025-09-30	54,918,701	90,050,973	60.99%
2025-06-30	54,308,961	90,009,625	60.34%
2025-03-31	51,280,494	89,537,171	57.27%
2024-12-31	49,929,022	23,712,220	210.56%
2024-09-30	860,232	8,882,570	9.68%
2024-06-30	836,496	7,535,667	11.10%
2024-03-31	184,157	6,340,697	2.90%
2023-12-31	210,606	6,028,210	3.49%
2023-09-30	413,556	6,162,671	6.71%
2023-06-30	709,183	6,162,280	11.51%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Inhibikase Therapeutics, Inc. (IKT) — SEC Financial Statements & Analysis

Inhibikase Therapeutics, Inc. (IKT) is a biological products, (no diagnostic substances) company, incorporated in DE. Inhibikase Therapeutics, Inc. trades on Nasdaq as: IKT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Inhibikase Therapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.07x, a Price-to-Sales (P/S) ratio of 11547340.58x (TTM), a Price-to-Book (P/B) ratio of 2.31x (TTM), at a market cap of $354.38M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.07x
P/S TTM: 11547340.58x
P/B TTM: 2.31x
Market Cap: $354.38M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Inhibikase Therapeutics, Inc. in?

Inhibikase Therapeutics, Inc. (IKT) operates in the Biological Products, (No Diagnostic Substances) industry.

What is IKT's market cap?

Inhibikase Therapeutics, Inc. (IKT) has a market capitalization of $354.38M as of 2026-06-30.

What exchange does IKT trade on?

Inhibikase Therapeutics, Inc. (IKT) trades on the Nasdaq.

Where is Inhibikase Therapeutics, Inc. incorporated?

Inhibikase Therapeutics, Inc. is incorporated in DE.